Should You Buy the Dip in Eli Lilly Stock Now?

Reported 21 days ago

Eli Lilly's stock has experienced a significant drop of up to 14% following disappointing Q3 earnings, primarily due to supply-demand issues for its diabetes and obesity drugs. Despite this sell-off, the company's management is taking steps to enhance manufacturing capacity and expand distribution channels, which could stabilize prices. With new medications approved and a share buyback program announced, many analysts believe this dip presents a favorable buying opportunity for long-term investors.

Source: YAHOO

View details

You may also interested in these wikis

Back to all Wikis